Trial Profile

A double-blind, prospective, randomised study of BIO89-100 in NASH

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegozafermin (Primary)
Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use

Most Recent Events

15 Nov 2021 Results of this post-hoc analysis presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
26 Jun 2021 Results presented at The International Liver Congress 2021
10 May 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com